FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387206688> ?p ?o ?g. }

• W4387206688 endingPage "e178" @default.
• W4387206688 startingPage "e177" @default.
• W4387206688 abstract "Radiation induced fibrosis (RIF) is a common long term adverse event in patients undergoing post-mastectomy radiation therapy (PMRT) which can cause capsular contracture, implant loss, and reconstruction complications in women with implant-based breast reconstruction. At a molecular level, adenosine is a driver of RIF. Preclinical data have shown that pharmacologic blockade of the adenosine A2A Receptor (A2AR) in mice as well as an A2AR knockout mouse model prevented skin fibrosis associated with radiation injury. Caffeine is an A2AR antagonist which has been shown to block the development of hepatic fibrosis in liver disease patients. We present a phase II placebo controlled clinical trial to evaluate whether a caffeine-based cream can prevent RIF and thus reduce the rates of reconstructive complications in patients with tissue expander-based reconstruction requiring PMRT.Women ≥ 18 years old with breast carcinoma stage 0-III status post mastectomy with tissue expander-based reconstruction who require PMRT to the chest wall +/- the regional nodes are being enrolled. The target accrual is 60 patients. Boost field to the chest wall, scar and/or nodal region is allowed. Patients with inflammatory breast cancer or those requiring skin bolus are excluded. Prior to starting radiation, patients will be randomized to placebo vs. caffeine cream and they will be instructed to apply the cream twice a day starting on the first day of radiation treatment and continuing daily for the duration of radiation until the removal of tissue expanders. The primary study endpoint is reconstructive complications requiring rehospitalization or reoperation by 2 years post radiation including reconstructive failure with or without reconstruction. A safety endpoint of grade ≥ 2 acute radiation dermatitis will also serve as a co-primary endpoint. Secondary endpoints are wound infection/cellulitis, hematoma, seroma, threatened exposure, wound dehiscence, implant leakage, rupture, and or deflation, and capsular contracture that do not meet criteria for the primary endpoint. Clinician rated cosmesis, local recurrence, regional recurrence, distant metastasis and survival up to 4 years are additional secondary endpoints. Exploratory endpoint includes the use of shear wave elastography (SWE) as a potential tool to quantitatively measure post irradiation fibrosis. Correlative aims include assessing epidermal thickness and fat layer thickness from tissue obtained at time of implant exchange for association with the development of fibrosis. The primary efficacy endpoint will be estimated using Kaplan Meier methods from date of randomization. Treatment comparisons will be based on a 2-sided log rank chi-square test and the hazard ratio will be estimated with 95% confidence intervals. The study started accruing in 12/2019 and is estimated to end by 04/2024. As of January 2023, 67% (40/60 patients) of the planned patients have been enrolled.To be determined.To be determined." @default.
• W4387206688 created "2023-09-30" @default.
• W4387206688 creator A5006177746 @default.
• W4387206688 creator A5020607218 @default.
• W4387206688 creator A5024436099 @default.
• W4387206688 creator A5045890439 @default.
• W4387206688 creator A5058616337 @default.
• W4387206688 creator A5059516590 @default.
• W4387206688 creator A5059576639 @default.
• W4387206688 creator A5066281483 @default.
• W4387206688 date "2023-10-01" @default.
• W4387206688 modified "2023-10-04" @default.
• W4387206688 title "A Phase II, Randomized, Double Blind, Placebo Controlled Study of the Safety and Efficacy of a Caffeine-Based Antifibrosis Cream in Patients with Breast Cancer Undergoing Radiation Therapy" @default.
• W4387206688 doi "https://doi.org/10.1016/j.ijrobp.2023.06.1026" @default.
• W4387206688 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37784794" @default.
• W4387206688 hasPublicationYear "2023" @default.
• W4387206688 type Work @default.
• W4387206688 citedByCount "0" @default.
• W4387206688 crossrefType "journal-article" @default.
• W4387206688 hasAuthorship W4387206688A5006177746 @default.
• W4387206688 hasAuthorship W4387206688A5020607218 @default.
• W4387206688 hasAuthorship W4387206688A5024436099 @default.
• W4387206688 hasAuthorship W4387206688A5045890439 @default.
• W4387206688 hasAuthorship W4387206688A5058616337 @default.
• W4387206688 hasAuthorship W4387206688A5059516590 @default.
• W4387206688 hasAuthorship W4387206688A5059576639 @default.
• W4387206688 hasAuthorship W4387206688A5066281483 @default.
• W4387206688 hasConcept C121608353 @default.
• W4387206688 hasConcept C126322002 @default.
• W4387206688 hasConcept C141071460 @default.
• W4387206688 hasConcept C142724271 @default.
• W4387206688 hasConcept C168563851 @default.
• W4387206688 hasConcept C197934379 @default.
• W4387206688 hasConcept C203092338 @default.
• W4387206688 hasConcept C204787440 @default.
• W4387206688 hasConcept C27081682 @default.
• W4387206688 hasConcept C2775951664 @default.
• W4387206688 hasConcept C2777757722 @default.
• W4387206688 hasConcept C2780559512 @default.
• W4387206688 hasConcept C2781001896 @default.
• W4387206688 hasConcept C509974204 @default.
• W4387206688 hasConcept C530470458 @default.
• W4387206688 hasConcept C71924100 @default.
• W4387206688 hasConceptScore W4387206688C121608353 @default.
• W4387206688 hasConceptScore W4387206688C126322002 @default.
• W4387206688 hasConceptScore W4387206688C141071460 @default.
• W4387206688 hasConceptScore W4387206688C142724271 @default.
• W4387206688 hasConceptScore W4387206688C168563851 @default.
• W4387206688 hasConceptScore W4387206688C197934379 @default.
• W4387206688 hasConceptScore W4387206688C203092338 @default.
• W4387206688 hasConceptScore W4387206688C204787440 @default.
• W4387206688 hasConceptScore W4387206688C27081682 @default.
• W4387206688 hasConceptScore W4387206688C2775951664 @default.
• W4387206688 hasConceptScore W4387206688C2777757722 @default.
• W4387206688 hasConceptScore W4387206688C2780559512 @default.
• W4387206688 hasConceptScore W4387206688C2781001896 @default.
• W4387206688 hasConceptScore W4387206688C509974204 @default.
• W4387206688 hasConceptScore W4387206688C530470458 @default.
• W4387206688 hasConceptScore W4387206688C71924100 @default.
• W4387206688 hasIssue "2" @default.
• W4387206688 hasLocation W43872066881 @default.
• W4387206688 hasLocation W43872066882 @default.
• W4387206688 hasOpenAccess W4387206688 @default.
• W4387206688 hasPrimaryLocation W43872066881 @default.
• W4387206688 hasRelatedWork W1997493124 @default.
• W4387206688 hasRelatedWork W2062035065 @default.
• W4387206688 hasRelatedWork W2072838952 @default.
• W4387206688 hasRelatedWork W2090513554 @default.
• W4387206688 hasRelatedWork W2158142243 @default.
• W4387206688 hasRelatedWork W3016928775 @default.
• W4387206688 hasRelatedWork W3025662173 @default.
• W4387206688 hasRelatedWork W3092031889 @default.
• W4387206688 hasRelatedWork W4308254070 @default.
• W4387206688 hasRelatedWork W58103817 @default.
• W4387206688 hasVolume "117" @default.
• W4387206688 isParatext "false" @default.
• W4387206688 isRetracted "false" @default.
• W4387206688 workType "article" @default.